AstraZeneca inks cancer deals with Bind and Horizon

New Drug Approvals

AstraZeneca inks cancer deals with Bind and Horizon

AstraZeneca has signed a nanomedicines pact with Bind Therapeutics in a deal which could be worth $200 million to the privately-held US biopharma firm.

The firms will work together to develop what Bind calls an “Accurin”, a  targeted and programmable cancer nanomedicine, based on a kinase inhibitor owned by the Anglo-Swedish drugmaker……………………..READ MORE AT PHARMATIMES

http://www.pharmatimes.com/Article/13-04-22/AstraZeneca_inks_cancer_deals_with_Bind_and_Horizon.aspx

 

View original post

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s